Publications by authors named "Ashraf I Reyad"
Background A2/A2B to B kidney transplantation has the potential to increase transplant access for traditionally disadvantaged blood group B minority candidates. Despite prior reports of positive post-transplant safety and clinical success, A2/A2B to B kidney transplantation remains underutilized in the United States. This study aims to investigate the post-transplant outcomes of A2/A2B to B kidney transplants performed at our center.
View Article and Find Full Text PDFArticle Synopsis
- Subclinical antibody-mediated rejection (ABMR) in kidney transplant patients presents diagnostic challenges, often requiring invasive procedures for detection, which are underutilized in the U.S. transplant centers.* -
- A 67-year-old patient showed high levels of donor-derived cell-free DNA (dd-cfDNA) after three months, but traditional biopsy did not indicate rejection, while advanced molecular histology did reveal rejection.* -
- The case demonstrates that using dd-cfDNA alongside molecular histology can improve early detection and treatment of graft injury, potentially enhancing patient and graft outcomes.*
Currently, there are more than 100,000 patients on the transplant waitlist in the United States. There exists a significant gap between the supply and demand for kidney transplants. Despite this, about a quarter of kidneys recovered from deceased donors are not being utilized.
View Article and Find Full Text PDFObjectives: The number of elderly kidney transplant recipients is increasing, and age-tailored induction immunosuppression regimens are needed. We compared safety and efficacy of basiliximab versus thymoglobulin at various dosages.
Materials And Methods: Of 590 kidney transplants at our center from 2012 to 2019, 119 (20.
Data describing outcomes of solid organ transplant (SOT) recipients with coronavirus disease 2019 (COVID-19) are variable, and the association between SOT status and mortality remains unclear. In this study, we compare clinical outcomes of SOT recipients hospitalized with COVID-19 between March 10, and September 1, 2020, to a matched cohort of non-SOT recipients at a national healthcare system in the United States (US). From a population of 43 461 hospitalized COVID-19-positive patients, we created a coarsened exact matched cohort of 4035 patients including 128 SOT recipients and 3907 weighted matched non-SOT controls.
View Article and Find Full Text PDF